Browsing Tag
AstraZeneca
162 posts
AVCT stock near 52-week high as Avacta Group pre|CISION data challenges Enhertu benchmark at AACR 2026
Avacta Group (AIM: AVCT) AACR 2026 data show AVA6103 outperforms Enhertu on tumor selectivity while AVA6207 delivers first in vivo dual payload results. Read our analysis.
Senhwa Biosciences expands CX-5461 into photodynamic therapy as AACR 2026 spotlight raises strategic optionality
Senhwa Biosciences expands CX-5461 into photodynamic therapy. Discover how this dual-mechanism strategy could reshape oncology innovation today.
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
NovelMed Therapeutics advances Ruxoprubart with Phase II PNH results and a subcutaneous trial. Discover how it could reshape the complement inhibitor market.
Jacobio Pharma secures $2bn global licensing agreement with AstraZeneca for JAB-23E73
Jacobio Pharma’s $2B global licensing deal with AstraZeneca could reshape KRAS inhibitor strategy in oncology. Read the full breakdown of the partnership now.
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.
AstraZeneca and Daiichi Sankyo win FDA approval for Enhertu combo as new standard in HER2 mBC
Enhertu plus pertuzumab gets FDA approval for first-line HER2-positive mBC, setting a new standard in metastatic breast cancer care. Read what changes now.
Saphnelo self-injection authorized in EU: AstraZeneca expands delivery options for lupus
Find out how AstraZeneca’s self-injection approval for Saphnelo could expand lupus treatment access and reshape biologic therapy delivery in Europe.
AstraZeneca (LSE: AZN) goes big on U.S. supply chain with latest $2bn manufacturing push
AstraZeneca invests $2B in Maryland to expand biologics and rare disease drug manufacturing. Find out what this means for U.S. jobs and the pharma supply chain.
New Baxdrostat Phase III data reveal significant ambulatory blood pressure reduction in resistant patients
Find out how AstraZeneca’s Baxdrostat achieved significant blood pressure reductions in resistant hypertension patients in Phase III trials.
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space.